GSK3B and uses thereof in the diagnostic and treatment of hypopigmentation disorders
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), University De Nice Sophia Antipolis, Chu De Nice
InventorsThierry Passeron, Florence Joly
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Claims1
A method for treating a vitiligo hypopigmentation lesion in a subject by inducing differentiation of melanocyte stem cells, comprising:
- administering to the subject an inhibitor of GSK3B in an amount sufficient to induce differentiation of melanocyte stem cells, wherein the inhibitor is selected from lithium chloride (LiCl) and CHIR99021.
Dependencies are inferred from the claim text.